zika
viru
zikv
mosquitoborn
flaviviru
famili
flavivirida
affect
human
adult
caus
syndrom
also
induc
microcephali
death
congenit
expos
fetus
recent
zikv
outbreak
south
america
result
unpreced
larg
number
infect
case
zikv
emerg
public
health
threat
current
countermeasur
avail
prevent
treatment
zikv
infect
except
symptom
relief
manag
vaccin
develop
still
earli
stage
unknown
approv
zikv
vaccin
avail
address
unmet
biomed
need
product
therapeut
antibodi
sab
biotherapeut
inc
develop
transchromosom
tc
bovin
platform
capabl
produc
larg
quantiti
fullyhuman
polyclon
antibodi
tc
bovin
tcb
system
bovin
immunoglobulin
gene
genet
inactiv
ig
function
reconstitut
human
artifici
chromosom
hac
compris
entir
unrearrang
human
immunoglobulin
repertoir
demonstr
physiolog
level
fullyhuman
polyclon
antibodi
produc
blood
tcb
also
tcb
hyperimmun
antigen
choic
produc
highli
potent
antigenspecif
human
polyclon
antibodi
antibodi
success
use
treat
list
viral
bacteri
infect
recent
demonstr
antizikv
human
polyclon
antibodi
produc
tcb
administ
dpi
provid
protect
zikv
infect
wild
type
mice
treat
antiinterferon
receptor
antibodi
homozyg
knockout
ifnar
mice
elimin
zikv
induc
tissu
damag
brain
testi
meantim
effort
develop
novel
anim
model
viral
infect
develop
signal
transduc
activ
transcript
gene
knockout
ko
golden
syrian
hamster
compar
commonli
use
ifnar
mice
model
viral
infect
either
type
interferon
ifnar
mice
type
type
ii
interferon
receptor
knock
mice
ko
hamster
partial
defect
type
interferon
signal
thu
less
immunocompromis
abovement
mous
model
furthermor
zikv
well
sever
flavivirus
exert
infect
human
target
human
protein
inactiv
human
type
interferon
respons
infect
ko
hamster
zikv
would
mimic
innat
immun
respons
human
upon
zikv
infect
inde
recent
demonstr
ko
hamster
highli
suscept
zikv
infect
use
novel
ko
hamster
first
nonmurin
rodent
model
viral
infect
recent
demonstr
infect
pregnant
hamster
lead
vertic
transmiss
zikv
uteru
placenta
immun
privileg
site
test
fetal
brain
present
studi
evalu
antizikv
human
polyclon
antibodi
produc
tcb
therapeut
prophylact
treatment
zikv
infect
ko
hamster
demonstr
treatment
provid
signific
protect
lethal
infect
zikv
ko
hamster
model
also
protect
test
zikv
infect
anim
treat
late
three
day
postinfect
dpi
zikv
use
studi
zikv
strain
origin
isol
puerto
rico
blood
human
patient
decemb
viru
provid
barbara
johnson
center
diseas
control
prevent
fort
collin
usa
viru
stock
prepar
two
passag
vero
cell
titer
cell
cultur
infecti
dose
ml
tcb
use
studi
carri
human
artifici
chromosom
hac
compris
entir
human
ig
gene
repertoir
germlin
genom
configur
genet
background
endogen
bovin
immunoglobulin
gene
ighm
igl
sequenti
knock
gener
antizikv
human
polyclon
antibodi
tcb
describ
previous
briefli
plasmid
dna
pdna
encod
fulllength
zikv
prme
gene
describ
hooper
et
al
use
vaccin
immun
tcb
tcb
hyperimmun
time
interv
antigen
mg
per
anim
per
vaccin
use
pharmajet
im
inject
devic
previous
describ
zikvspecif
antibodi
term
purifi
plasma
collect
hyperimmun
anim
neg
control
antibodi
use
studi
human
polyclon
antibodi
purifi
sera
tcb
zikv
immun
ko
golden
syrian
hamster
produc
inhous
use
studi
week
age
infect
pfu
zikv
administ
ko
hamster
subcutan
sc
rout
inguin
area
prophylact
therapeut
treatment
differ
dose
rang
mg
mgkg
administ
via
intraperiton
ip
inject
serum
separ
whole
blood
use
serum
separ
tube
centrifug
g
min
store
use
testicular
tissu
collect
quantifi
zikv
rna
zikvimmunohistochemistri
ihc
assay
histolog
analysi
rtpcr
tissu
homogen
microcentrifug
teflon
pestl
frozen
rna
extract
either
testi
anim
remain
tissu
testi
fix
use
freshli
prepar
paraformaldehyd
prior
public
laboratori
other
reiter
testi
one
target
organ
zikv
infect
rodent
therefor
use
testi
one
major
organ
evalu
tcb
antibodi
sex
suscept
diseas
lead
moribund
state
twentyfour
hour
later
tissu
rins
pb
place
ethanol
paraffinembed
tissu
section
thick
process
hematoxylineosin
stain
zikvimmunoreact
zikvir
assay
neutral
activ
hamster
serum
antibodi
determin
plaqu
reduct
assay
incub
min
serial
dilut
serum
mix
incub
overnight
stock
zikv
pfu
final
start
dilut
serum
sampl
total
volum
serum
pb
zikv
mixtur
ad
well
twelvewel
plate
contain
vero
cell
confluenc
plate
incub
h
period
rock
one
ml
agaros
overlay
media
ad
incub
three
day
later
cell
stain
crystal
violet
solut
contain
formaldehyd
plaqu
count
invers
dilut
caus
reduct
report
plaqu
reduct
neutral
titer
titer
infecti
viru
similarli
determin
except
serum
ad
sampl
serum
rna
extract
use
qiaamp
viral
rna
minikit
qiagen
qiagen
germantown
md
usa
fifti
mg
freshli
isol
tissu
ml
tissu
homogen
pestl
ad
trizol
molecular
research
center
cincinnati
oh
usa
rna
extract
rna
suspend
rnasecur
life
technolog
carlsbad
ca
usa
amplifi
quantit
rtpcr
ten
microlit
sensifasttm
probe
norox
onestep
mix
biolin
memphi
tn
usa
polymeras
revers
transcriptas
along
malaysian
zikv
primer
probe
label
fam
fluorophor
tamra
quencher
genscript
piscataway
nj
usa
respect
mix
extract
rna
sampl
run
duplic
rel
genom
equival
averag
gapdh
primer
probe
also
includ
zikv
rna
revers
transcrib
min
heat
min
pcr
amplif
cycl
cycl
standard
curv
zikv
rna
gapdh
rna
gener
serial
dilut
synthet
rna
genscript
piscataway
nj
usa
target
sequenc
access
dilut
normal
mous
total
rna
agil
technolog
santa
clara
ca
usa
thermocycl
qpcr
bio
molecular
system
taunton
usa
rel
number
zikv
rna
determin
standard
curv
normal
rel
total
rna
calcul
gapdh
standard
curv
previous
valid
gapdh
level
modifi
zikv
infect
limit
detect
calcul
base
titer
valu
sham
uninfect
testi
tissu
follow
deparaffin
tissu
section
block
normal
goat
serum
min
room
temperatur
either
mous
antiflaviviru
group
antigen
monoclon
antibodi
millipor
temecula
ca
usa
mous
monoclon
antibodi
zikv
protein
aalto
bio
reagent
dublin
ireland
incub
tissu
overnight
brief
wash
pb
section
incub
fluorescenceconjug
secondari
antibodi
invitrogen
grand
island
ny
usa
room
temperatur
h
imag
captur
use
zeiss
microscop
axiovis
process
use
adob
photoshop
hematoxylin
eosin
h
e
stain
perform
studi
morpholog
diagnos
tabl
read
veterinari
anatom
pathologist
dr
avw
experi
conduct
strict
accord
guidelin
aaalac
accredit
laboratori
anim
research
center
utah
state
univers
approv
institut
anim
care
use
committe
utah
state
univers
iacuc
protocol
approv
date
septemb
character
activ
neutral
antibodi
kinet
viremia
viral
presenc
testi
ko
hamster
follow
zikv
infect
infect
three
agematch
week
age
male
hamster
via
sc
rout
pfu
zikv
sera
collect
dpi
detect
neutral
antibodi
titer
base
data
figur
sera
assay
timepoint
detect
level
zikvspecif
neutral
antibodi
indic
infect
elicit
neutral
antibodi
respons
ko
hamster
signific
serum
viremia
also
found
dpi
anim
dpi
anim
figur
investig
zikv
infect
testi
testicl
harvest
dpi
zikv
rna
detect
immunohistochemistri
analysi
zikv
rna
level
significantli
higher
two
anim
right
left
testi
dpi
dpi
figur
part
testicular
tissu
anim
also
analyz
ihc
zikvir
neg
test
isol
dpi
posit
seminifer
tubul
dpi
dpi
possibl
infect
interstiti
cell
testi
figur
clearli
correl
presenc
zikv
rna
figur
test
indic
zikv
establish
infect
testi
earli
dpi
dpi
order
evalu
prophylact
efficaci
protect
ko
hamster
zikv
infect
equal
number
agematch
male
n
femal
n
hamster
age
prophylact
treat
singl
ip
inject
mgkg
one
day
prior
zikv
infect
sham
infect
control
group
three
hamster
sex
also
includ
shown
figur
anim
surviv
except
one
die
eye
bleed
procedur
wherea
anim
controlantibodi
treat
group
succumb
addit
anim
lose
weight
controlantibodi
treat
anim
start
lose
weight
dpi
continu
lose
weight
dpi
figur
ko
hamster
exhibit
conjunct
zikv
infect
significantli
reduc
anim
treat
prophylact
controlantibodi
treat
anim
free
conjunct
treat
anim
free
eye
diseas
figur
furthermor
anim
conjunct
becam
moribund
control
antibodytr
group
higher
titer
zikv
rna
detect
control
antibodi
treat
group
treat
group
figur
prnt
data
figur
suggest
prophylact
administr
dpi
singl
dose
mgkg
inhibit
zikv
replic
lead
effect
prophylact
protect
subsequ
conduct
experi
investig
efficaci
therapeut
treatment
zikv
infect
diseas
identifi
late
infect
effect
treatment
administ
equal
number
agematch
male
n
femal
n
ko
hamster
infect
zikv
follow
treatment
via
ip
rout
either
dpi
treatment
control
group
dpi
dpi
sham
infect
control
group
two
male
two
femal
hamster
shown
figur
singl
dose
administ
via
ip
inject
dose
mgkg
dpi
prevent
ko
hamster
becom
moribund
figur
wherea
neg
control
antibodi
treat
group
start
becom
moribund
dpi
data
indic
treatment
late
dpi
effect
protect
hamster
morbid
interest
note
judg
signific
p
improv
weight
chang
therapeut
treatment
dpi
provid
similar
protect
prophylact
treatment
dpi
figur
unclear
hamster
shaminfect
group
treat
dpi
gain
weight
specul
mostli
caus
handl
procedur
experi
yet
identifi
next
order
evalu
protect
effect
zikv
infect
testicular
tissu
rtpcr
ihc
perform
test
surviv
anim
end
experiment
period
dpi
shown
figur
administ
dpi
ko
hamster
result
undetect
zikv
rna
test
figur
contrari
high
level
zikv
rna
detect
testicular
tissu
collect
dpi
surviv
male
hamster
treat
dpi
figur
even
though
anim
treat
dpi
display
mortal
bodi
weight
loss
figur
b
suggest
zikv
cross
bloodtesti
barrier
persist
infect
seminifer
tubul
treatment
late
dpi
ineffect
viral
clearanc
histolog
also
show
one
four
anim
treat
dpi
sever
pyogranulomat
inflammatori
infiltr
figur
tabl
zikvir
indic
possibl
infect
interstiti
cell
well
cell
line
seminifer
tubul
figur
presenc
zikv
rna
figur
test
correspond
histolog
lesion
figur
zikvimmunoreact
figur
none
ko
hamster
treat
dpi
exhibit
lesion
figur
g
show
zikvimmunoreact
within
interstitium
seminifer
tubul
figur
g
data
indic
treatment
late
dpi
provid
complet
protect
zikv
infect
testi
two
four
anim
treat
dpi
pyogranulomat
inflamm
interstitium
seminifer
tubul
tabl
along
zikv
posit
cell
red
color
figur
even
though
anim
lose
weight
surviv
end
experiment
period
figur
suggest
ko
hamster
use
nonleth
anim
model
studi
antivir
vaccin
treatment
zikv
infect
demonstr
efficaci
singl
dose
mgkg
administ
dpi
prevent
morbid
testicular
infect
investig
whether
singl
treatment
higher
dose
could
elimin
testicular
infect
lower
dose
still
prevent
anim
weight
loss
toward
goal
test
mgkg
mgkg
higher
dose
mgkg
lower
dose
surviv
figur
weight
loss
figur
percentag
free
diseas
sign
figur
rtpcr
zikv
rna
figur
evalu
treatment
group
also
perform
h
e
ihc
analys
testicular
tissu
dpi
higher
dose
group
tabl
dose
mgkg
treatment
administ
dpi
prevent
anim
morbid
figur
howev
signific
weight
loss
observ
low
dose
group
anim
start
dpi
figur
anim
show
diseas
sign
figur
comparison
treatment
higher
dose
mgml
mgkg
provid
nearli
protect
morbid
figur
margin
allevi
weight
loss
diseas
sign
figur
shown
figur
high
level
zikv
rna
still
detect
dpi
testicular
tissu
hamster
treat
higher
dose
dpi
even
though
mortal
observ
detect
zikv
rna
consist
detect
patholog
lesion
posit
zikvir
organ
summar
tabl
indic
dpi
neither
two
test
higher
dose
provid
complet
protect
zikv
infect
testi
sever
mous
model
zikv
infect
ifnar
tripl
ko
wt
mice
treat
type
ifnblock
antibodi
report
varieti
treatment
strategi
includ
small
molecul
antivir
antibodi
recent
report
adult
ko
hamster
highli
suscept
zikv
infect
zikv
rna
titer
detect
testi
kidney
brain
spinal
cord
infect
ko
hamster
compar
ko
mice
develop
uniform
lethal
phenotyp
upon
zikv
infect
ko
hamster
infect
zikv
succumb
figur
onset
death
delay
day
hamster
mous
side
side
comparison
ko
mous
model
ko
hamster
model
challeng
strain
zikv
would
interest
investig
differ
speci
develop
pathogenesi
zikv
infect
sinc
ko
hamster
often
surviv
durat
experiment
period
ie
dpi
viral
rna
present
testi
brain
organ
uniqu
hamster
model
provid
opportun
test
efficaci
prophylact
therapeut
treatment
antizikv
antibodi
current
fda
approv
zikv
vaccin
antivir
drug
avail
therefor
urgent
need
develop
effici
control
strategi
emerg
pathogen
number
antivir
shown
activ
zikv
infect
immunodefici
ifnar
immunocompet
mous
model
apart
antivir
antibodi
inactiv
fc
receptor
also
shown
protect
immunocompromis
immunocompet
pregnant
rodent
model
convalesc
sera
zikvinfect
patient
monoclon
antibodi
denv
patient
mab
human
antisera
test
differ
strain
zikv
viru
sever
mous
model
hundr
monoclon
antibodi
target
e
protein
zikv
neutral
activ
either
deriv
human
patient
mice
also
identifi
primat
model
administr
cocktail
potent
neutral
monoclon
antibodi
collect
zikvinfect
patient
complet
prevent
serum
viremia
present
studi
use
uniqu
hamster
model
investig
prophylact
therapeut
effect
zikv
infect
particularli
focus
potenti
elimin
zikv
testi
gather
preliminari
scientif
inform
potenti
use
treat
sexual
transmiss
first
character
kinet
viremia
develop
neutral
antibodi
presenc
viru
ko
hamster
follow
zikv
infect
establish
endogen
antizikv
neutral
antibodi
respons
elicit
dpi
viral
rna
zikvir
testi
also
detect
time
window
test
whether
singl
dose
administ
prophylact
dpi
would
abl
protect
hamster
morbid
weight
loss
conjunct
result
show
prophylact
treatment
dpi
dose
effect
prevent
hamster
mortal
figur
weight
loss
figur
well
reduct
diseas
sign
conjunct
figur
base
data
appear
prophylact
treatment
tcb
antibodi
effect
countermeasur
zikv
infect
howev
studi
nonhuman
primat
model
clinic
trial
need
conduct
test
possibl
studi
kinet
viremia
time
frame
effect
treat
zikv
infect
also
provid
valuabl
data
therapeut
intervent
could
effect
strike
treatment
singl
dose
mgkg
late
dpi
still
fulli
protect
anim
morbid
even
though
anim
high
level
zikv
rna
posit
zikvir
testicular
tissu
dpi
furthermor
data
show
singl
therapeut
treatment
dpi
prevent
anim
zikvir
testi
develop
histopatholog
lesion
provid
possibl
sexual
transmiss
zikv
could
prevent
treatment
administ
earli
enough
post
infect
summari
first
demonstr
zikv
infect
immunotherapi
new
rodent
anim
model
ko
hamster
accord
fda
anim
efficaci
rule
develop
therapeut
intervent
seriou
condit
caus
zikv
demonstr
efficaci
one
anim
speci
second
demonstr
highli
effect
prophylact
therapeut
treat
zikv
infect
hamster
model
contrast
animalderiv
monoclon
antibodi
fullyhuman
nonimmunogen
patient
polyclon
recogn
multipl
antigen
viru
effect
reduc
elimin
viral
evas
caus
viral
mutat
produc
quickli
larg
quantiti
g
fulli
human
immunoglobulin
produc
per
tc
bovin
per
month
unpublish
observ
advantag
antivir
therapi
could
potenti
make
well
tcb
platform
power
countermeasur
fight
zikv
infect
worth
note
tcb
deriv
fulli
human
polyclon
antibodi
elicit
sever
virus
bacteria
shown
effect
treat
infect
caus
variou
infecti
pathogen
tcb
antibodi
alreadi
proven
safe
efficaci
human
clinic
trial
antizikv
tcb
antibodi
report
studi
yet
test
rigor
human
clinic
trial
proven
effect
treat
zikv
human
infect
